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survival beneﬁt, and identiﬁcation of this subset would also have sig-
niﬁcant clinical beneﬁt. Toward this end, we have used matrix-assisted 
laser desorption/ionization time-of-ﬂight mass spectrometry (MALDI 
MS) as a rapid, affordable and simple strategy that can be applied to the 
analysis of complex biological samples such as serum, urine and tissue. 
Peaks in the mass spectrum correspond to ions formed from relatively 
abundant species in the sample, predominantly peptides and proteins. 
We have used MALDI MS to study unfractionated, pretreatment sera to 
identify NSCLC patients with improved survival after treatment with 
the EGFR TKIs geﬁtinib and erlotinib(1). Mass spectra, independently 
acquired at two institutions, gave highly concordant results, and were 
used to generate an algorithm predictive of time to progression and sur-
vival. This prediction algorithm was then validated in a blinded manner 
in two independent cohorts of NSCLC patients treated with EGFR 
TKIs. This classiﬁcation algorithm did not predict outcome in three 
independent cohorts of patients who did not receive treatment with 
EGFR TKIs. Thus, if upheld in prospective clinical trials, this simple, 
rapid, and inexpensive analysis of pre-treatment peripheral blood might 
be useful in selecting therapy for advanced non-small cell lung cancer 
patients.
1. Taguchi F, Solomon B, Gregorc V, et al. Mass Spectrometry to Classify NSCLC 
Patients for Clinical Outcome after Treatment with EGFR Tyrosine Kinase Inhibitors: A 
Multi-Cohort Cross Institutional Study. J Natl Cancer Inst 2007;In press.
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Non-small cell lung cancer (NSCLC) constitutes approximately 80% 
of all lung cancers, and tumor stage is the primary determinant of prog-
nosis for these patients (1). The term “early stage” has been commonly 
used to represent stage I and II patients. These are patients who have 
potentially curable disease by complete surgical resection. However, 
the overall prognosis of these early stage patients remains relatively 
poor with 5-year survival rates of 30-60% (2). Variation in survival 
largely reﬂects heterogeneity in the tumor biology, with some tumors 
having more aggressive growth and greater metastatic potential than 
others. While histology subtypes and grades demonstrate some impact 
on the prognosis of NSCLC patients, the overall differences are not 
sufﬁciently great to affect treatment decisions (3). An ability to identify 
molecular characteristics that can improve the classiﬁcation of patient 
prognosis additional to tumor stage would provide the rationale for ad-
juvant therapy to patients with the signiﬁcantly poorer prognosis. With 
recent trials showing that adjuvant chemotherapy signiﬁcantly improve 
the survival of stage II-IIIA patients, the development of molecular 
prognostic markers has assume some urgency. 
The ﬁrst evidence that a molecular aberration in lung cancer can be a 
prognostic marker was the KRAS oncogene. Slebos et al (4) reported 
that oncogenic KRAS mutations occurred in 30% of lung adenocar-
cinoma and its presence deﬁned a subgroup of patients with very 
poor prognosis. Since then, more than ﬁfty retrospective and mostly 
institutional-based studies were conducted to validate this report, but 
they provided contradicting results. A meta-analysis on 23 PCR-based 
studies (2632 patients) involving NSCLC patients and 11 studies (1170 
patients) involving only adenocarcinoma patients recorded RAS muta-
tion hazard ratios (HR) of 1.39 (95% conﬁdence interval 1.22 - 1.58; 
p=0.03) and 1.50 (95% CI 1.26-1.80; p=0.1), respectively (5). These 
results strongly suggest that RAS mutation is a poor prognostic marker 
in NSCLC patients. However, the only two studies that involved phase 
III randomized adjuvant clinical trial patients, the ECOG E4592 (6) 
and NCIC CTG JBR.10 (7) trials, failed to show a prognostic value for 
RAS mutation. 
Similar to RAS, abnormal p53 protein expression and p53 gene muta-
tions have been extensively investigated for their prognostic value in 
early stage resected NSCLC patients. Despite discrepancies among 
individual studies, results of two meta-analyses involving overlapping 
published data provided strong evidence that both abnormal p53 protein 
expression (positive immunohistochemistry) and p53 gene mutation are 
poor prognostic markers, and the impact appears greater in adenocar-
cinoma compared to squamous cell carcinoma (8, 9). Nevertheless, 
neither RAS and p53 mutation analyses nor p53 immunohistochemistry 
are routinely performed in clinical practice, as further evidence of their 
impact on patient selection for adjuvant chemotherapy is needed. 
Over the last two decades, there has been an exponential growth in our 
knowledge of the nature of human genome, genes that make up our 
chromosomes, molecular signaling pathways that regulate cellular pro-
cesses, and aberrations in the genetic and signaling networks in cancers 
and cancer cells. With completion of the human genome project, the 
identiﬁcation of all 30-50 thousand human genes is nearly complete. 
Microarray technologies were developed to facilitate the evaluation of 
this new genetic information at a genome-wide scale. The ﬁrst series 
of microarray studies in lung cancer demonstrated that gene expression 
proﬁling was able to distinguish different histological types of lung 
cancers (10, 11). These and other studies also reported that there are 
expression signatures that can identify patients with signiﬁcantly differ-
ent prognosis (12,13). However, it soon became apparent that the sets 
of prognostic signature genes from different studies showed minimal 
overlaps. Furthermore, analyses of a microarray dataset using differ-
ent statistical or computational algorithms could yield different sets of 
putatively prognostic gene signatures (14,15). The apparent discrepan-
cies between these studies were attributed putatively to variability in 
microarray platforms used, data processing, analytical algorithm and 
demographic differences in the patient cohorts studied. Nevertheless, 
these studies provided the important proof of principle that microar-
rays could yield biologically relevant information for deﬁning tumor 
characteristics beyond histology. While the initial prognostic signatures 
are composed of hundreds to thousands of gene probes, validation 
of these microarray results using the more quantitative assay called 
reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
led to the identiﬁcation of smaller sets of prognostic gene classiﬁers, 
but further conﬁrmation of the latter in separate cohorts of patients was 
challenging (16,17). More recently, seemingly more rational approach-
es to identify prognostic gene classiﬁers based on patients’ extreme 
survival outcomes (18,19) or tumor cell biology (20) has revealed 
novel genomic classiﬁers that could be validated in independent patient 
cohorts. The ﬁdelity of these classiﬁers in additional large independent 
patient/sample datasets generated in other laboratories remains to be 
conﬁrmed.
While the above gene expression proﬁling studies are mRNA based, 
more recent efforts have used microarray platforms that can proﬁle 
changes in genome wide gene copy number changes (array-compara-
tive genomic hybridization/CGH) and single nucleotide polymorphisms 
(SNP) (21,22). Since DNA is more stable than RNA, these studies may 
be more easily performed using DNA isolated from formalin-ﬁxed 
and parafﬁn embedded archival tumor samples. Array-CGH studies 
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performed on DNA of lung cancer cell lines and primary tumors have 
demonstrated non-random and consistent gains and losses of genetic 
materials on various chromosomal arms (23-25). Large gains indicate 
gene ampliﬁcation, some of which represent potential oncogenes. 
In contrast, genes that are commonly lost have a high probability of 
being tumor suppressor genes. One of the chromosomal arms that 
show a high frequency of genetic gains in non-small cell lung cancer 
is 5p (short arm). Zhu et al (26,27) has previously demonstrated that 
overexpression and/or high ampliﬁcation of two genes located on 5p, 
Skp2 (5p13) and hTERT (5p15) are associated with poor prognosis 
in a subgroup of NSCLC patients. Future studies will likely identify 
additional genomic copy signatures that could be strong classiﬁers for 
patients with signiﬁcantly different clinical outcomes. 
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Sleeve lobectomy for lung cancer was ﬁrst described as a compro-
mise operation for patients whose pulmonary reserve was considered 
inadequate to permit pneumonectomy. Since then, several authors have 
suggested that sleeve resection may provide as good if not better results 
than pneumonectomy in selected cases of primary lung cancer involving 
the proximal bronchial tree. Whether sleeve resection is radical enough 
and indicated for patients who could tolerate pneumonectomy contin-
ues to be debated among thoracic surgeons and indeed there are only 
a handful of reports of clinical series comparing operative mortality, 
survival, and sites of recurrences between these procedures (Table 1).
Table 1 - Comparison of survival between sleeve resection and  
pneumonectomy
Authors (yr) No pts 5 year survival (%)
Sleeve resection Pneumonectomy
Gaissert (1996) 128 42 % 44 %
Yoshino (1997) 58 66 % 59 %
Suen (1999) 200 38 % 36 %
Ludwig (2005) 310 39 % 27 %
Takeda (2006) 172 54 % 33 %
Operative mortality, survival, and sites of recurrences were compared 
in 1,346 consecutive patients who underwent pneumonectomy (N : 
1,046) or sleeve resection in our institution over a 25-year interval 
(Table 2).
